Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBD in First-Line Multiple Myeloma
NCT01056276Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- May 2010
- Primary completion
- Aug 2015
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bendamustine, bortezomib in multiple myeloma (MM), sponsored by SCRI Development Innovations. Started May 2010; status: completed.
02
Drugs
bendamustinebortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01056276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01056276.